Liver Cancer Therapies 2022

Friday, December 9, 2022, 9:00 AM - 5:00 PM, Hybrid Conference, Baltimore, MD


Liver Cancer remains challenging condition with high morbidity and mortality. Incidence of liver cancer is increasing in the US. There are clinical advancements and new research for liver cancer that can assist clinicians in treating patients. However, may clinicians are not aware of the latest advancements in treatments and research.   
University of Maryland has one of the top liver transplant programs and cancer centers with active liver cancer research and coordinated liver cancer treatment program; a multi-disciplinary Liver Cancer Clinic is planned.  Learning such wealth of research and clinical advancements for liver cancer will benefit patients in the state of MD and beyond as well as clinicians caring for those patients.

1. At the conclusion of this activity, participants will be able to:
2. 1. Discuss the scope of liver cancer program at UMMC and affiliated hospitals.
3. 2. Describe key directions in current liver cancer research.
4. 3. Identify new directions in treatments for liver cancer.

The University of Maryland School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Maryland School of Medicine designates this Live activity for a maximum of 6.50 AMA PRA Category 1 Credits ^TM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AMA PRA Category 1 Credits™ (6.50 hours), Non-Physician Attendance (6.50 hours)

You are not logged in.

Please click the button below to login or create a new account before continuing.

Mitigation of Relevant Financial Relationships

University of Maryland School of Medicine adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

No faculty are available for this activity at this time.

Exhibit at this Event